THE COST EFFECTIVENESS ANALYSIS OF THE ORAL ANTI-VIRAL TREATMENTS ALTERNATIVES FOR THE CHRONIC HEPATITIS B IN TURKEY

被引：0
|
作者：
Kockaya, G. [1 ]
Kose, A. [1 ]
Dalgic, C. [1 ]
Yenilmez, F. B. [2 ]
Ozdemir, O. [3 ]
Kucuksayrac, E. [1 ]
Tayfun, K. [1 ]
机构：
[1] Gilead Sci, Istanbul, Turkey
[2] Hacettepe Univ, Ankara, Turkey
[3] Yorum Consultancy, Istanbul, Turkey
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.823
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI26
引用
收藏
页码：A367 / A367
页数：1
相关论文
共 50 条
  • [31] The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4
    Kamal, S. M.
    Kassim, S.
    EL Gohary, E.
    Fouad, A.
    Nabegh, L.
    Hafez, T.
    Bahnasy, K.
    Hassan, H.
    Ghoraba, D.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 307 - 318
  • [32] EVALUATION OF COST-EFFECTIVENESS OF CHRONIC HEPATITIS B TREATMENTS: ENTECAVIR AND TELBIVUDINE
    Suh, J. K.
    Hay, J.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A72 - A72
  • [33] Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
    Yakubu, I.
    Zhang, Y.
    Ijioma, S.
    Carroll, N. V.
    Patterson, J.
    Sterling, R.
    Gupta, G.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 483 - 483
  • [34] High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments
    Nien, Hsiao-Ching
    Hsu, Shih-Jer
    Su, Tung-Hung
    Yang, Po-Jen
    Sheu, Jin-Chuan
    Wang, Jin-Town
    Chow, Lu-Ping
    Chen, Chi-Ling
    Kao, Jia-Horng
    Yang, Wei-Shiung
    [J]. PLOS ONE, 2017, 12 (01):
  • [35] In vitro anti-viral activity of thymalfasin against hepatitis B
    Tuthill, CW
    Martins, EB
    Rudolph, AR
    [J]. HEPATOLOGY, 2002, 36 (04) : 639A - 639A
  • [36] Anti-viral resistance testing in hepatitis B virus infection
    Bozdayi, M.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2009, 46 : S3 - S3
  • [37] A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
    Spackman, D. Eldon
    Veenstra, David L.
    [J]. PHARMACOECONOMICS, 2008, 26 (11) : 937 - 949
  • [38] A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
    D. Eldon Spackman
    David L. Veenstra
    [J]. PharmacoEconomics, 2008, 26 : 937 - 949
  • [39] Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada
    He, Jing
    Bowen, James M.
    Xie, Feng
    Goeree, Ron
    [J]. VALUE IN HEALTH, 2012, 15 (06) : 894 - 906
  • [40] Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase
    Zhao, Qingqing
    Liu, Kehui
    Zhu, Xiaojun
    Yan, Lei
    Ding, Yezhou
    Xu, Yumin
    Lou, Shike
    Zhao, Gangde
    Xie, Qing
    Gao, Yueqiu
    Bao, Shisan
    Wang, Hui
    [J]. ANTIVIRAL RESEARCH, 2020, 184
12345